【市場調査レポート】第I～IV相臨床開発サービスのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Phase I - IV Clinical Development Services Market Insights, Forecast to 2028

QYResearchが調査・発行した産業分析レポートです。第I～IV相臨床開発サービスのグローバル市場インサイト・予測（～2028年） / Global Phase I - IV Clinical Development Services Market Insights, Forecast to 2028 / QY2207E10464資料のイメージです。

• レポートコード：QY2207E10464
• 出版社/出版日：QYResearch / 2022年7月
• レポート形態：英文、PDF、126ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

新型コロナウイルス感染症のパンデミックにより、世界の第I～IV相臨床開発サービスの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に第I～IV相臨床開発サービスの世界市場のxxx％を占める「初期段階」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「製薬会社」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
中国の第I～IV相臨床開発サービスの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの第I～IV相臨床開発サービス市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの第I～IV相臨床開発サービス市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

第I～IV相臨床開発サービスのグローバル主要メーカーには、Syneos Health、PPD、GVI CDS、Parexel、Clinical Leader、Thermo Fisher Scientific、LabCorp、Worldwide Clinical Trial、CROS NT、Dynakin、Rho, Inc.、Synteract、ICBio CRO、Sofpromed、Profil、ICON Plc、Clinipace、OCT Clinical、EPS Group、Beijing Sun-novo Pharmaceutical Research、Dmedglobal、WuXi AppTec、Elixir Clinical Researchなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

第I～IV相臨床開発サービス市場は、種類と用途によって区分されます。世界の第I～IV相臨床開発サービス市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
初期段階、段階II-III、段階IIIb-IV

【用途別セグメント】
製薬会社、医療機器会社、委託研究機関

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 第I～IV相臨床開発サービス製品概要
- 種類別市場（初期段階、段階II-III、段階IIIb-IV）
- 用途別市場（製薬会社、医療機器会社、委託研究機関）
- 調査の目的
・エグゼクティブサマリー
- 世界の第I～IV相臨床開発サービス販売量予測2017-2028
- 世界の第I～IV相臨床開発サービス売上予測2017-2028
- 第I～IV相臨床開発サービスの地域別販売量
- 第I～IV相臨床開発サービスの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別第I～IV相臨床開発サービス販売量
- 主要メーカー別第I～IV相臨床開発サービス売上
- 主要メーカー別第I～IV相臨床開発サービス価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（初期段階、段階II-III、段階IIIb-IV）
- 第I～IV相臨床開発サービスの種類別販売量
- 第I～IV相臨床開発サービスの種類別売上
- 第I～IV相臨床開発サービスの種類別価格
・用途別市場規模（製薬会社、医療機器会社、委託研究機関）
- 第I～IV相臨床開発サービスの用途別販売量
- 第I～IV相臨床開発サービスの用途別売上
- 第I～IV相臨床開発サービスの用途別価格
・北米市場
- 北米の第I～IV相臨床開発サービス市場規模（種類別、用途別）
- 主要国別の第I～IV相臨床開発サービス市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの第I～IV相臨床開発サービス市場規模（種類別、用途別）
- 主要国別の第I～IV相臨床開発サービス市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の第I～IV相臨床開発サービス市場規模（種類別、用途別）
- 主要国別の第I～IV相臨床開発サービス市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の第I～IV相臨床開発サービス市場規模（種類別、用途別）
- 主要国別の第I～IV相臨床開発サービス市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの第I～IV相臨床開発サービス市場規模（種類別、用途別）
- 主要国別の第I～IV相臨床開発サービス市場規模（トルコ、サウジアラビア）
・企業情報
Syneos Health、PPD、GVI CDS、Parexel、Clinical Leader、Thermo Fisher Scientific、LabCorp、Worldwide Clinical Trial、CROS NT、Dynakin、Rho, Inc.、Synteract、ICBio CRO、Sofpromed、Profil、ICON Plc、Clinipace、OCT Clinical、EPS Group、Beijing Sun-novo Pharmaceutical Research、Dmedglobal、WuXi AppTec、Elixir Clinical Research
・産業チェーン及び販売チャネル分析
- 第I～IV相臨床開発サービスの産業チェーン分析
- 第I～IV相臨床開発サービスの原材料
- 第I～IV相臨床開発サービスの生産プロセス
- 第I～IV相臨床開発サービスの販売及びマーケティング
- 第I～IV相臨床開発サービスの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 第I～IV相臨床開発サービスの産業動向
- 第I～IV相臨床開発サービスのマーケットドライバー
- 第I～IV相臨床開発サービスの課題
- 第I～IV相臨床開発サービスの阻害要因
・主な調査結果

Market Analysis and Insights: Global Phase I – IV Clinical Development Services Market
The global Phase I – IV Clinical Development Services market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Early Phase accounting for % of the Phase I – IV Clinical Development Services global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pharmaceutical Companies segment is altered to an % CAGR throughout this forecast period.
China Phase I – IV Clinical Development Services market size is valued at US$ million in 2021, while the North America and Europe Phase I – IV Clinical Development Services are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Phase I – IV Clinical Development Services landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Phase I – IV Clinical Development Services market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Phase I – IV Clinical Development Services market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Phase I – IV Clinical Development Services market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Phase I – IV Clinical Development Services market.
Global Phase I – IV Clinical Development Services Scope and Market Size
Phase I – IV Clinical Development Services market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Phase I – IV Clinical Development Services market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Early Phase
Phase II-III
Phase IIIb-IV
Segment by Application
Pharmaceutical Companies
Medical Device Companies
Contract Research Organizations
By Company
Syneos Health
PPD
GVI CDS
Parexel
Clinical Leader
Thermo Fisher Scientific
LabCorp
Worldwide Clinical Trial
CROS NT
Dynakin
Rho, Inc.
Synteract
ICBio CRO
Sofpromed
Profil
ICON Plc
Clinipace
OCT Clinical
EPS Group
Beijing Sun-novo Pharmaceutical Research
Dmedglobal
WuXi AppTec
Elixir Clinical Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Phase I – IV Clinical Development Services Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Early Phase
1.2.3 Phase II-III
1.2.4 Phase IIIb-IV
1.3 Market by Application
1.3.1 Global Phase I – IV Clinical Development Services Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pharmaceutical Companies
1.3.3 Medical Device Companies
1.3.4 Contract Research Organizations
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Phase I – IV Clinical Development Services Market Perspective (2017-2028)
2.2 Phase I – IV Clinical Development Services Growth Trends by Region
2.2.1 Phase I – IV Clinical Development Services Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Phase I – IV Clinical Development Services Historic Market Size by Region (2017-2022)
2.2.3 Phase I – IV Clinical Development Services Forecasted Market Size by Region (2023-2028)
2.3 Phase I – IV Clinical Development Services Market Dynamics
2.3.1 Phase I – IV Clinical Development Services Industry Trends
2.3.2 Phase I – IV Clinical Development Services Market Drivers
2.3.3 Phase I – IV Clinical Development Services Market Challenges
2.3.4 Phase I – IV Clinical Development Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Phase I – IV Clinical Development Services Players by Revenue
3.1.1 Global Top Phase I – IV Clinical Development Services Players by Revenue (2017-2022)
3.1.2 Global Phase I – IV Clinical Development Services Revenue Market Share by Players (2017-2022)
3.2 Global Phase I – IV Clinical Development Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Phase I – IV Clinical Development Services Revenue
3.4 Global Phase I – IV Clinical Development Services Market Concentration Ratio
3.4.1 Global Phase I – IV Clinical Development Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Phase I – IV Clinical Development Services Revenue in 2021
3.5 Phase I – IV Clinical Development Services Key Players Head office and Area Served
3.6 Key Players Phase I – IV Clinical Development Services Product Solution and Service
3.7 Date of Enter into Phase I – IV Clinical Development Services Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Phase I – IV Clinical Development Services Breakdown Data by Type
4.1 Global Phase I – IV Clinical Development Services Historic Market Size by Type (2017-2022)
4.2 Global Phase I – IV Clinical Development Services Forecasted Market Size by Type (2023-2028)
5 Phase I – IV Clinical Development Services Breakdown Data by Application
5.1 Global Phase I – IV Clinical Development Services Historic Market Size by Application (2017-2022)
5.2 Global Phase I – IV Clinical Development Services Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Phase I – IV Clinical Development Services Market Size (2017-2028)
6.2 North America Phase I – IV Clinical Development Services Market Size by Type
6.2.1 North America Phase I – IV Clinical Development Services Market Size by Type (2017-2022)
6.2.2 North America Phase I – IV Clinical Development Services Market Size by Type (2023-2028)
6.2.3 North America Phase I – IV Clinical Development Services Market Share by Type (2017-2028)
6.3 North America Phase I – IV Clinical Development Services Market Size by Application
6.3.1 North America Phase I – IV Clinical Development Services Market Size by Application (2017-2022)
6.3.2 North America Phase I – IV Clinical Development Services Market Size by Application (2023-2028)
6.3.3 North America Phase I – IV Clinical Development Services Market Share by Application (2017-2028)
6.4 North America Phase I – IV Clinical Development Services Market Size by Country
6.4.1 North America Phase I – IV Clinical Development Services Market Size by Country (2017-2022)
6.4.2 North America Phase I – IV Clinical Development Services Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Phase I – IV Clinical Development Services Market Size (2017-2028)
7.2 Europe Phase I – IV Clinical Development Services Market Size by Type
7.2.1 Europe Phase I – IV Clinical Development Services Market Size by Type (2017-2022)
7.2.2 Europe Phase I – IV Clinical Development Services Market Size by Type (2023-2028)
7.2.3 Europe Phase I – IV Clinical Development Services Market Share by Type (2017-2028)
7.3 Europe Phase I – IV Clinical Development Services Market Size by Application
7.3.1 Europe Phase I – IV Clinical Development Services Market Size by Application (2017-2022)
7.3.2 Europe Phase I – IV Clinical Development Services Market Size by Application (2023-2028)
7.3.3 Europe Phase I – IV Clinical Development Services Market Share by Application (2017-2028)
7.4 Europe Phase I – IV Clinical Development Services Market Size by Country
7.4.1 Europe Phase I – IV Clinical Development Services Market Size by Country (2017-2022)
7.4.2 Europe Phase I – IV Clinical Development Services Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Phase I – IV Clinical Development Services Market Size (2017-2028)
8.2 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Type
8.2.1 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Phase I – IV Clinical Development Services Market Share by Type (2017-2028)
8.3 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Application
8.3.1 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Phase I – IV Clinical Development Services Market Share by Application (2017-2028)
8.4 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Region
8.4.1 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Phase I – IV Clinical Development Services Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Phase I – IV Clinical Development Services Market Size (2017-2028)
9.2 Latin America Phase I – IV Clinical Development Services Market Size by Type
9.2.1 Latin America Phase I – IV Clinical Development Services Market Size by Type (2017-2022)
9.2.2 Latin America Phase I – IV Clinical Development Services Market Size by Type (2023-2028)
9.2.3 Latin America Phase I – IV Clinical Development Services Market Share by Type (2017-2028)
9.3 Latin America Phase I – IV Clinical Development Services Market Size by Application
9.3.1 Latin America Phase I – IV Clinical Development Services Market Size by Application (2017-2022)
9.3.2 Latin America Phase I – IV Clinical Development Services Market Size by Application (2023-2028)
9.3.3 Latin America Phase I – IV Clinical Development Services Market Share by Application (2017-2028)
9.4 Latin America Phase I – IV Clinical Development Services Market Size by Country
9.4.1 Latin America Phase I – IV Clinical Development Services Market Size by Country (2017-2022)
9.4.2 Latin America Phase I – IV Clinical Development Services Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Phase I – IV Clinical Development Services Market Size (2017-2028)
10.2 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Type
10.2.1 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Phase I – IV Clinical Development Services Market Share by Type (2017-2028)
10.3 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Application
10.3.1 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Phase I – IV Clinical Development Services Market Share by Application (2017-2028)
10.4 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Country
10.4.1 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Phase I – IV Clinical Development Services Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Syneos Health
11.1.1 Syneos Health Company Details
11.1.2 Syneos Health Business Overview
11.1.3 Syneos Health Phase I – IV Clinical Development Services Introduction
11.1.4 Syneos Health Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.1.5 Syneos Health Recent Developments
11.2 PPD
11.2.1 PPD Company Details
11.2.2 PPD Business Overview
11.2.3 PPD Phase I – IV Clinical Development Services Introduction
11.2.4 PPD Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.2.5 PPD Recent Developments
11.3 GVI CDS
11.3.1 GVI CDS Company Details
11.3.2 GVI CDS Business Overview
11.3.3 GVI CDS Phase I – IV Clinical Development Services Introduction
11.3.4 GVI CDS Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.3.5 GVI CDS Recent Developments
11.4 Parexel
11.4.1 Parexel Company Details
11.4.2 Parexel Business Overview
11.4.3 Parexel Phase I – IV Clinical Development Services Introduction
11.4.4 Parexel Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.4.5 Parexel Recent Developments
11.5 Clinical Leader
11.5.1 Clinical Leader Company Details
11.5.2 Clinical Leader Business Overview
11.5.3 Clinical Leader Phase I – IV Clinical Development Services Introduction
11.5.4 Clinical Leader Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.5.5 Clinical Leader Recent Developments
11.6 Thermo Fisher Scientific
11.6.1 Thermo Fisher Scientific Company Details
11.6.2 Thermo Fisher Scientific Business Overview
11.6.3 Thermo Fisher Scientific Phase I – IV Clinical Development Services Introduction
11.6.4 Thermo Fisher Scientific Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.6.5 Thermo Fisher Scientific Recent Developments
11.7 LabCorp
11.7.1 LabCorp Company Details
11.7.2 LabCorp Business Overview
11.7.3 LabCorp Phase I – IV Clinical Development Services Introduction
11.7.4 LabCorp Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.7.5 LabCorp Recent Developments
11.8 Worldwide Clinical Trial
11.8.1 Worldwide Clinical Trial Company Details
11.8.2 Worldwide Clinical Trial Business Overview
11.8.3 Worldwide Clinical Trial Phase I – IV Clinical Development Services Introduction
11.8.4 Worldwide Clinical Trial Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.8.5 Worldwide Clinical Trial Recent Developments
11.9 CROS NT
11.9.1 CROS NT Company Details
11.9.2 CROS NT Business Overview
11.9.3 CROS NT Phase I – IV Clinical Development Services Introduction
11.9.4 CROS NT Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.9.5 CROS NT Recent Developments
11.10 Dynakin
11.10.1 Dynakin Company Details
11.10.2 Dynakin Business Overview
11.10.3 Dynakin Phase I – IV Clinical Development Services Introduction
11.10.4 Dynakin Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.10.5 Dynakin Recent Developments
11.11 Rho, Inc.
11.11.1 Rho, Inc. Company Details
11.11.2 Rho, Inc. Business Overview
11.11.3 Rho, Inc. Phase I – IV Clinical Development Services Introduction
11.11.4 Rho, Inc. Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.11.5 Rho, Inc. Recent Developments
11.12 Synteract
11.12.1 Synteract Company Details
11.12.2 Synteract Business Overview
11.12.3 Synteract Phase I – IV Clinical Development Services Introduction
11.12.4 Synteract Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.12.5 Synteract Recent Developments
11.13 ICBio CRO
11.13.1 ICBio CRO Company Details
11.13.2 ICBio CRO Business Overview
11.13.3 ICBio CRO Phase I – IV Clinical Development Services Introduction
11.13.4 ICBio CRO Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.13.5 ICBio CRO Recent Developments
11.14 Sofpromed
11.14.1 Sofpromed Company Details
11.14.2 Sofpromed Business Overview
11.14.3 Sofpromed Phase I – IV Clinical Development Services Introduction
11.14.4 Sofpromed Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.14.5 Sofpromed Recent Developments
11.15 Profil
11.15.1 Profil Company Details
11.15.2 Profil Business Overview
11.15.3 Profil Phase I – IV Clinical Development Services Introduction
11.15.4 Profil Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.15.5 Profil Recent Developments
11.16 ICON Plc
11.16.1 ICON Plc Company Details
11.16.2 ICON Plc Business Overview
11.16.3 ICON Plc Phase I – IV Clinical Development Services Introduction
11.16.4 ICON Plc Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.16.5 ICON Plc Recent Developments
11.17 Clinipace
11.17.1 Clinipace Company Details
11.17.2 Clinipace Business Overview
11.17.3 Clinipace Phase I – IV Clinical Development Services Introduction
11.17.4 Clinipace Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.17.5 Clinipace Recent Developments
11.18 OCT Clinical
11.18.1 OCT Clinical Company Details
11.18.2 OCT Clinical Business Overview
11.18.3 OCT Clinical Phase I – IV Clinical Development Services Introduction
11.18.4 OCT Clinical Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.18.5 OCT Clinical Recent Developments
11.19 EPS Group
11.19.1 EPS Group Company Details
11.19.2 EPS Group Business Overview
11.19.3 EPS Group Phase I – IV Clinical Development Services Introduction
11.19.4 EPS Group Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.19.5 EPS Group Recent Developments
11.20 Beijing Sun-novo Pharmaceutical Research
11.20.1 Beijing Sun-novo Pharmaceutical Research Company Details
11.20.2 Beijing Sun-novo Pharmaceutical Research Business Overview
11.20.3 Beijing Sun-novo Pharmaceutical Research Phase I – IV Clinical Development Services Introduction
11.20.4 Beijing Sun-novo Pharmaceutical Research Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.20.5 Beijing Sun-novo Pharmaceutical Research Recent Developments
11.21 Dmedglobal
11.21.1 Dmedglobal Company Details
11.21.2 Dmedglobal Business Overview
11.21.3 Dmedglobal Phase I – IV Clinical Development Services Introduction
11.21.4 Dmedglobal Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.21.5 Dmedglobal Recent Developments
11.22 WuXi AppTec
11.22.1 WuXi AppTec Company Details
11.22.2 WuXi AppTec Business Overview
11.22.3 WuXi AppTec Phase I – IV Clinical Development Services Introduction
11.22.4 WuXi AppTec Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.22.5 WuXi AppTec Recent Developments
11.23 Elixir Clinical Research
11.23.1 Elixir Clinical Research Company Details
11.23.2 Elixir Clinical Research Business Overview
11.23.3 Elixir Clinical Research Phase I – IV Clinical Development Services Introduction
11.23.4 Elixir Clinical Research Revenue in Phase I – IV Clinical Development Services Business (2017-2022)
11.23.5 Elixir Clinical Research Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Phase I - IV Clinical Development Services Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Early Phase
Table 3. Key Players of Phase II-III
Table 4. Key Players of Phase IIIb-IV
Table 5. Global Phase I - IV Clinical Development Services Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Phase I - IV Clinical Development Services Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Phase I - IV Clinical Development Services Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Phase I - IV Clinical Development Services Market Share by Region (2017-2022)
Table 9. Global Phase I - IV Clinical Development Services Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Phase I - IV Clinical Development Services Market Share by Region (2023-2028)
Table 11. Phase I - IV Clinical Development Services Market Trends
Table 12. Phase I - IV Clinical Development Services Market Drivers
Table 13. Phase I - IV Clinical Development Services Market Challenges
Table 14. Phase I - IV Clinical Development Services Market Restraints
Table 15. Global Phase I - IV Clinical Development Services Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Phase I - IV Clinical Development Services Revenue Share by Players (2017-2022)
Table 17. Global Top Phase I - IV Clinical Development Services by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Phase I - IV Clinical Development Services as of 2021)
Table 18. Ranking of Global Top Phase I - IV Clinical Development Services Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Phase I - IV Clinical Development Services Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Phase I - IV Clinical Development Services Product Solution and Service
Table 22. Date of Enter into Phase I - IV Clinical Development Services Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Phase I - IV Clinical Development Services Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Phase I - IV Clinical Development Services Revenue Market Share by Type (2017-2022)
Table 26. Global Phase I - IV Clinical Development Services Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Phase I - IV Clinical Development Services Revenue Market Share by Type (2023-2028)
Table 28. Global Phase I - IV Clinical Development Services Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Phase I - IV Clinical Development Services Revenue Share by Application (2017-2022)
Table 30. Global Phase I - IV Clinical Development Services Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Phase I - IV Clinical Development Services Revenue Share by Application (2023-2028)
Table 32. North America Phase I - IV Clinical Development Services Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Phase I - IV Clinical Development Services Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Phase I - IV Clinical Development Services Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Phase I - IV Clinical Development Services Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Phase I - IV Clinical Development Services Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Phase I - IV Clinical Development Services Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Phase I - IV Clinical Development Services Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Phase I - IV Clinical Development Services Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Phase I - IV Clinical Development Services Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Phase I - IV Clinical Development Services Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Phase I - IV Clinical Development Services Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Phase I - IV Clinical Development Services Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Phase I - IV Clinical Development Services Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Phase I - IV Clinical Development Services Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Phase I - IV Clinical Development Services Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Phase I - IV Clinical Development Services Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Phase I - IV Clinical Development Services Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Phase I - IV Clinical Development Services Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Phase I - IV Clinical Development Services Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Phase I - IV Clinical Development Services Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Phase I - IV Clinical Development Services Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Phase I - IV Clinical Development Services Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Phase I - IV Clinical Development Services Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Phase I - IV Clinical Development Services Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Phase I - IV Clinical Development Services Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Phase I - IV Clinical Development Services Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Phase I - IV Clinical Development Services Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Phase I - IV Clinical Development Services Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Phase I - IV Clinical Development Services Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Phase I - IV Clinical Development Services Market Size by Country (2023-2028) & (US$ Million)
Table 62. Syneos Health Company Details
Table 63. Syneos Health Business Overview
Table 64. Syneos Health Phase I - IV Clinical Development Services Product
Table 65. Syneos Health Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 66. Syneos Health Recent Developments
Table 67. PPD Company Details
Table 68. PPD Business Overview
Table 69. PPD Phase I - IV Clinical Development Services Product
Table 70. PPD Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 71. PPD Recent Developments
Table 72. GVI CDS Company Details
Table 73. GVI CDS Business Overview
Table 74. GVI CDS Phase I - IV Clinical Development Services Product
Table 75. GVI CDS Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 76. GVI CDS Recent Developments
Table 77. Parexel Company Details
Table 78. Parexel Business Overview
Table 79. Parexel Phase I - IV Clinical Development Services Product
Table 80. Parexel Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 81. Parexel Recent Developments
Table 82. Clinical Leader Company Details
Table 83. Clinical Leader Business Overview
Table 84. Clinical Leader Phase I - IV Clinical Development Services Product
Table 85. Clinical Leader Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 86. Clinical Leader Recent Developments
Table 87. Thermo Fisher Scientific Company Details
Table 88. Thermo Fisher Scientific Business Overview
Table 89. Thermo Fisher Scientific Phase I - IV Clinical Development Services Product
Table 90. Thermo Fisher Scientific Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 91. Thermo Fisher Scientific Recent Developments
Table 92. LabCorp Company Details
Table 93. LabCorp Business Overview
Table 94. LabCorp Phase I - IV Clinical Development Services Product
Table 95. LabCorp Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 96. LabCorp Recent Developments
Table 97. Worldwide Clinical Trial Company Details
Table 98. Worldwide Clinical Trial Business Overview
Table 99. Worldwide Clinical Trial Phase I - IV Clinical Development Services Product
Table 100. Worldwide Clinical Trial Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 101. Worldwide Clinical Trial Recent Developments
Table 102. CROS NT Company Details
Table 103. CROS NT Business Overview
Table 104. CROS NT Phase I - IV Clinical Development Services Product
Table 105. CROS NT Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 106. CROS NT Recent Developments
Table 107. Dynakin Company Details
Table 108. Dynakin Business Overview
Table 109. Dynakin Phase I - IV Clinical Development Services Product
Table 110. Dynakin Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 111. Dynakin Recent Developments
Table 112. Rho, Inc. Company Details
Table 113. Rho, Inc. Business Overview
Table 114. Rho, Inc. Phase I - IV Clinical Development Services Product
Table 115. Rho, Inc. Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 116. Rho, Inc. Recent Developments
Table 117. Synteract Company Details
Table 118. Synteract Business Overview
Table 119. Synteract Phase I - IV Clinical Development Services Product
Table 120. Synteract Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 121. Synteract Recent Developments
Table 122. ICBio CRO Company Details
Table 123. ICBio CRO Business Overview
Table 124. ICBio CRO Phase I - IV Clinical Development Services Product
Table 125. ICBio CRO Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 126. ICBio CRO Recent Developments
Table 127. Sofpromed Company Details
Table 128. Sofpromed Business Overview
Table 129. Sofpromed Phase I - IV Clinical Development Services Product
Table 130. Sofpromed Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 131. Sofpromed Recent Developments
Table 132. Profil Company Details
Table 133. Profil Business Overview
Table 134. Profil Phase I - IV Clinical Development Services Product
Table 135. Profil Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 136. Profil Recent Developments
Table 137. ICON Plc Company Details
Table 138. ICON Plc Business Overview
Table 139. ICON Plc Phase I - IV Clinical Development Services Product
Table 140. ICON Plc Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 141. ICON Plc Recent Developments
Table 142. Clinipace Company Details
Table 143. Clinipace Business Overview
Table 144. Clinipace Phase I - IV Clinical Development Services Product
Table 145. Clinipace Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 146. Clinipace Recent Developments
Table 147. OCT Clinical Company Details
Table 148. OCT Clinical Business Overview
Table 149. OCT Clinical Phase I - IV Clinical Development Services Product
Table 150. OCT Clinical Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 151. OCT Clinical Recent Developments
Table 152. EPS Group Company Details
Table 153. EPS Group Business Overview
Table 154. EPS Group Phase I - IV Clinical Development Services Product
Table 155. EPS Group Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 156. EPS Group Recent Developments
Table 157. Beijing Sun-novo Pharmaceutical Research Company Details
Table 158. Beijing Sun-novo Pharmaceutical Research Business Overview
Table 159. Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Product
Table 160. Beijing Sun-novo Pharmaceutical Research Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 161. Beijing Sun-novo Pharmaceutical Research Recent Developments
Table 162. Dmedglobal Company Details
Table 163. Dmedglobal Business Overview
Table 164. Dmedglobal Phase I - IV Clinical Development Services Product
Table 165. Dmedglobal Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 166. Dmedglobal Recent Developments
Table 167. WuXi AppTec Company Details
Table 168. WuXi AppTec Business Overview
Table 169. WuXi AppTec Phase I - IV Clinical Development Services Product
Table 170. WuXi AppTec Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 171. WuXi AppTec Recent Developments
Table 172. Elixir Clinical Research Company Details
Table 173. Elixir Clinical Research Business Overview
Table 174. Elixir Clinical Research Phase I - IV Clinical Development Services Product
Table 175. Elixir Clinical Research Revenue in Phase I - IV Clinical Development Services Business (2017-2022) & (US$ Million)
Table 176. Elixir Clinical Research Recent Developments
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Phase I - IV Clinical Development Services Market Share by Type: 2021 VS 2028
Figure 2. Early Phase Features
Figure 3. Phase II-III Features
Figure 4. Phase IIIb-IV Features
Figure 5. Global Phase I - IV Clinical Development Services Market Share by Application: 2021 VS 2028
Figure 6. Pharmaceutical Companies Case Studies
Figure 7. Medical Device Companies Case Studies
Figure 8. Contract Research Organizations Case Studies
Figure 9. Phase I - IV Clinical Development Services Report Years Considered
Figure 10. Global Phase I - IV Clinical Development Services Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Phase I - IV Clinical Development Services Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Phase I - IV Clinical Development Services Market Share by Region: 2021 VS 2028
Figure 13. Global Phase I - IV Clinical Development Services Market Share by Players in 2021
Figure 14. Global Top Phase I - IV Clinical Development Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Phase I - IV Clinical Development Services as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Phase I - IV Clinical Development Services Revenue in 2021
Figure 16. North America Phase I - IV Clinical Development Services Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America Phase I - IV Clinical Development Services Market Size Market Share by Type (2017-2028)
Figure 18. North America Phase I - IV Clinical Development Services Market Size Market Share by Application (2017-2028)
Figure 19. North America Phase I - IV Clinical Development Services Market Size Share by Country (2017-2028)
Figure 20. United States Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Phase I - IV Clinical Development Services Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe Phase I - IV Clinical Development Services Market Size Market Share by Type (2017-2028)
Figure 24. Europe Phase I - IV Clinical Development Services Market Size Market Share by Application (2017-2028)
Figure 25. Europe Phase I - IV Clinical Development Services Market Size Share by Country (2017-2028)
Figure 26. Germany Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Phase I - IV Clinical Development Services Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific Phase I - IV Clinical Development Services Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific Phase I - IV Clinical Development Services Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific Phase I - IV Clinical Development Services Market Size Share by Region (2017-2028)
Figure 36. China Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 42. Latin America Phase I - IV Clinical Development Services Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America Phase I - IV Clinical Development Services Market Size Market Share by Type (2017-2028)
Figure 44. Latin America Phase I - IV Clinical Development Services Market Size Market Share by Application (2017-2028)
Figure 45. Latin America Phase I - IV Clinical Development Services Market Size Share by Country (2017-2028)
Figure 46. Mexico Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Phase I - IV Clinical Development Services Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa Phase I - IV Clinical Development Services Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa Phase I - IV Clinical Development Services Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa Phase I - IV Clinical Development Services Market Size Share by Country (2017-2028)
Figure 52. Turkey Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE Phase I - IV Clinical Development Services Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Syneos Health Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 56. PPD Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 57. GVI CDS Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 58. Parexel Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 59. Clinical Leader Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 60. Thermo Fisher Scientific Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 61. LabCorp Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 62. Worldwide Clinical Trial Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 63. CROS NT Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 64. Dynakin Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 65. Rho, Inc. Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 66. Synteract Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 67. ICBio CRO Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 68. Sofpromed Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 69. Profil Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 70. ICON Plc Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 71. Clinipace Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 72. OCT Clinical Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 73. EPS Group Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 74. Beijing Sun-novo Pharmaceutical Research Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 75. Dmedglobal Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 76. WuXi AppTec Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 77. Elixir Clinical Research Revenue Growth Rate in Phase I - IV Clinical Development Services Business (2017-2022)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed

以下、関連資料のご紹介

インシリコ臨床試験のグローバル市場インサイト・予測（～2028年）

Global In Silico Clinical Trials Market Insights, Forecast to 2028
QY2207E09237 2022年7月 114Pages
新型コロナウイルス感染症のパンデミックにより、世界のインシリコ臨床試験の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にインシリコ臨床試験...

治験患者募集サービスのグローバル市場インサイト・予測（～2028年）

Global Clinical Trial Patient Recruitment Services Market Insights, Forecast to 2028
QY2207C3475 2022年7月11日 126Pages
新型コロナウイルス感染症のパンデミックにより、世界の治験患者募集サービスの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に治験患者募集サー...

臨床試験募集＆管理サービスのグローバル市場インサイト・予測（～2028年）

Global Clinical Trial Recruitment and Management Services Market Insights, Forecast to 2028
QY2207C3476 2022年7月11日 127Pages
新型コロナウイルス感染症のパンデミックにより、世界の臨床試験募集＆管理サービスの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に臨床試験募...

臨床フローサイトメトリーのグローバル市場インサイト・予測（～2028年）

Global Clinical Flow Cytometry Market Insights, Forecast to 2028
QY2207C3689 2022年7月11日 75Pages
新型コロナウイルス感染症のパンデミックにより、世界の臨床フローサイトメトリーの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に臨床フローサ...

臨床診断用ティンパノメーターのグローバル市場インサイト・予測（～2028年）

Global Clinical Tympanometer Market Insights, Forecast to 2028
QY2207C3690 2022年7月11日 112Pages
新型コロナウイルス感染症のパンデミックにより、世界の臨床診断用ティンパノメーターの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に臨床診断...

インシリコ臨床試験のグローバル市場インサイト・予測（～2028年） An in silico clinical trial, also known as a virtual clinical trial, is an individualized computer simulation used in the development or regulatory evaluation of a medicinal product, device, or intervention. While completely simulated clinical trials are not feasible with current technology and unde…
治験患者募集サービスのグローバル市場インサイト・予測（～2028年） Clinical trial patient recruitment companies use a range of methods, from digital advertising to community partnerships, to find the right patients for your trial. The global market has noticed significant growth owing to the increasing rate of clinical trials, and the rapid growth of the medical an…
臨床試験募集＆管理サービスのグローバル市場インサイト・予測（～2028年） Clinical trial patient recruitment companies use a range of methods, from digital advertising to community partnerships, to find the right patients for your trial. The global market has noticed significant growth owing to the increasing rate of clinical trials, and the rapid growth of the medical an…
高度相変化材料（PCM）の世界市場2022年-2030年 Summary: In this Advanced Phase Change Materials Market report, offers a comprehensive analysis of key market trends in the global Advanced Phase Change Materials market. It also includes discussion on historical trends, current market status, competitive landscape, growth opportunities and challeng…
世界の三相ペレタイザー市場予測（～2028年）：二軸ねじ、単軸ねじ The Three Phase Pelletizers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…